Ebola: Phase 1 Trial Of 2014 Virus Strain Vaccine Results
Wednesday, March 25, 2015 - 16:20
in Health & Medicine
The first phase 1 trial of an Ebola vaccine based on the current (2014) strain have shown it to be safe and provoke an immune response. The big question, whether it can protect against the Ebola virus, remain unanswered for now.A team of researchers led by Professor Fengcai Zhu, from the Jiangsu provincial center for disease prevention and control in China, tested the safety and immunogenicity of a novel Ebola vaccine, based on the 2014 Zaire Guinea Ebola strain, and delivered by a virus-like structure (known as a recombinant adenovirus type-5 vaccine). The experimental vaccine was developed by Beijing Institute of Biotechnology in Beijing, China, and Tianjin CanSino Biotechnology in Tianjin, China. read more